Effect of Direct-acting Antiviral Drugs on Erectile Function
NCT ID: NCT03444272
Last Updated: 2020-10-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
105 participants
INTERVENTIONAL
2018-01-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C
NCT03402165
Metabolic Changes in Chronic HCV Patients Receiving DAAS
NCT04211844
Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs
NCT03268317
Treatment of Hepatitis c by Using Direct-acting Antiviral
NCT05372874
Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination
NCT03490097
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hepatitis C Treatment
HCV Treatment (Sofosbuvir and Daklatasuvir)
Sofosbuvir and Daklatasuvir
HCV Treatment (Sofosbuvir and Daklatasuvir)
Supportive treatment
supportive liver therapy
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sofosbuvir and Daklatasuvir
HCV Treatment (Sofosbuvir and Daklatasuvir)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male
Exclusion Criteria
* Age below 18 years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Sherief Abd-Elsalam
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
PhDTropical Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sherief Abd-Elsalam, MD
Role: STUDY_CHAIR
Tanta University
Mohamed Alhefnawy, MD
Role: PRINCIPAL_INVESTIGATOR
Tanta University Faculty of medicine
Khaled Almekaty, MD
Role: PRINCIPAL_INVESTIGATOR
Tanta University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sherief Abd-Elsalam
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HCV TREATMENT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.